

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>		Application No. 10/647,544		Inventor Alexandros Makriyannis et al	
		Title Keto Cannabinoids With Therapeutic Indications			
		Filing Date 08/25/2003	Group Art Unit 1625	Docket No. UCONAP/207/US	
Mailed on: August 4, 2004					
<b>UNITED STATES PATENT DOCUMENTS</b>					
Examiner Initial	Document No.	Date	Name	Class	
CA	09/600786	11/24/99	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 00/32200 enclosed herewith)		
CA	09/701989	6/9/99	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 99/64389 enclosed herewith)		
CA	10/110865	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28497 enclosed herewith)		
CA	10/110830	10/18/00	<b>*1* Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28329 enclosed herewith)</b>		
CA	10/110812	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28498 enclosed herewith)		
CA	10/110862	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/29007 enclosed herewith)		
CA	10/111059	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28557 enclosed herewith)		
CA	10/483482	7/11/02	<b>*1* Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 03/005960 enclosed herewith)</b>		

INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Application No. 10/647,544	Inventor Alexandros Makriyannis et al	
			Title Keto Cannabinoids With Therapeutic Indications		
			Filing Date 08/25/2003	Group Art Unit 1625	Docket No. UCONAP/207/US
Mailed on: August 4, 2004					
CA	10/493093	10/28/02	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 03/35005 enclosed herewith)		
CA	10/790498	3/1/04	Makriyannis et al		
CA	2002/0119972	8/29/02	Leftheris et al		
CA	<b>2003/0120094</b>	<b>6/26/03</b>	<b>*1* Makriyannis et al</b>		
CA	2003/0149082	8/7/03	Makriyannis et al		
CA	2004/0077649	4/22/04	Makriyannis et al		
CA	2004/0077851	4/22/04	Makriyannis et al		
CA	2004/0087590	5/6/04	Makriyannis et al		
CA	3041343	6/26/62	Jucker et al		
CA	3465024	9/2/69	Brownstein et al		
CA	<b>3573327</b>	<b>3/30/71</b>	<b>*1* Miyano</b>		
CA	3577458	5/4/71	Brownstein et al		
CA	<b>3886184</b>	<b>5/27/75</b>	<b>*1* Matsumoto et al</b>		
CA	<b>3897306</b>	<b>7/29/75</b>	<b>*1* Vidic</b>		
CA	<b>3915996</b>	<b>10/28/75</b>	<b>*1* Wright</b>		
CA	3928598	12/23/75	Archer		
CA	3944673	3/16/76	Archer		
CA	3953603	4/27/76	Archer		
CA	<b>4036857</b>	<b>7/19/77</b>	<b>*1* Razdan et al</b>		
CA	4054582	10/18/77	Blanchard et al		
CA	4087545	5/2/78	Archer et al		
CA	4087546	5/2/78	Archer et al		
CA	4087547	5/2/78	Archer et al		
CA	4088777	5/9/78	Archer et al		
CA	4102902	7/25/78	Archer et al		
CA	4152450	5/1/79	Day et al		
CA	4171315	10/16/79	Ryan et al		
CA	<b>4176233</b>	<b>11/27/79</b>	<b>*1* Archer et al</b>		
CA	<b>4179517</b>	<b>12/18/79</b>	<b>*1* Mechoulam</b>		
CA	4188495	2/12/80	Althuis et al		
CA	4208351	6/17/80	Archer et al		
CA	4278603	7/14/81	Thakkar et al		
CA	4282248	8/4/81	Mechoulam et al		
CA	4395560	7/26/83	Ryan		

INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Application No. 10/647,544		Inventor Alexandros Makriyannis et al	
			Title Keto Cannabinoids With Therapeutic Indications			
			Filing Date 08/25/2003		Group Art Unit 1625	
Mailed on: August 4, 2004						
CA	4497827	2/5/85	Nelson			
CA	4550214	10/29/85	Mehta			
CA	4758597	7/19/88	Martin et al			
CA	4812457	3/14/89	Narumiya			
CA	4876276	10/24/89	*1* Mechoulam			
CA	4885295	12/5/89	Bell et al			
CA	5053548	10/1/91	Tanaka et al			
CA	5068234	11/26/91	D'Ambra et al			
CA	5147876	9/15/92	Mizuchi et al			
CA	5223510	6/29/93	Gubin et al			
CA	5284867	2/8/94	*1* Kloog			
CA	5324737	6/28/94	D'Ambra et al			
CA	5434295	7/18/95	Mechoulam et al			
CA	5440052	8/8/95	*1* Makriyannis et al			
CA	5462960	10/31/95	Barth et al			
CA	5489580	2/6/96	Makriyannis et al			
CA	5521215	5/28/96	Mechoulam			
CA	5532237	7/2/96	Gallant et al			
CA	5538993	7/23/96	*1* Mechoulam			
CA	5605906	2/25/97	Lau			
CA	5607933	3/4/97	D'Ambra et al			
CA	5618955	4/8/97	Mechoulam et al			
CA	5624941	4/29/97	*1* Barth et al			
CA	5635530	6/3/97	Mechoulam			
CA	5688825	11/18/97	Makriyannis et al			
CA	5747524	5/5/98	Cullinan et al			
CA	5744459		Makriyannis et al			
CA	5804601	9/8/98	Kato et al (appears equivalent to EP0737671)			
CA	5817651	10/6/98	D'Ambra et al			
CA	5872148	2/16/99	*1* Makriyannis et al			
CA	5874459	2/23/99	Makriyannis et al			
CA	5925628	7/20/99	Lee et al			
CA	5925768	7/20/99	Barth et al			
CA	5932610	8/3/99	*1* Shohami et al			
CA	5948777	9/7/99	Bender et al			

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>			Application No. 10/647,544		Inventor Alexandros Makriyannis et al	
			Title Keto Cannabinoids With Therapeutic Indications			
			Filing Date 08/25/2003		Group Art Unit 1625	
Mailed on: August 4, 2004						
CA	6013648	1/11/00	*1* Rinaldi et al (appears equivalent to FR2735774)			
CA	6028084	2/22/00	Barth et al			
CA	6096740	9/1/00	Mechoulam			
CA	6127399	10/3/00	Yuan			
CA	6166066	12/26/00	*1* Makriyannis et al			
CA	6284788	10/4/01	Mittendorf et al (appears equivalent to EP860168)			
CA	6391909	5/21/02	Makriyannis et al			
CA	6579900	6/17/03	Makriyannis et al			
CA	6610737	8/26/03	Garzon et al			
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initial	Document No.	Date	Country	Name		Translation
	EP0276732	8/3/88	EP	*1* Hoffman La Roche		
CA	EP0471609	6/29/93	EP	Gubin et al, in French, front page only (English bibliography and abstract, appears equivalent to US5223510)		
CA	EP0737671	10/16/96	EP	Takeda Chemical Industries, front page only (bibliography, appears equivalent to US 5804601)		
CA	EP0860168	9/4/01	EP	Mittendorf et al, in German, front page only (including English bibliography, appears equivalent to US6284788)		
CA	FR2240003	5/27/75	FR	*1* Matsumoto et al, in French (including English bibliography and abstract, appears equivalent to US3886184)		

INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Application No. 10/647,544		Inventor Alexandros Makriyannis et al	
			Title Keto Cannabinoids With Therapeutic Indications			
			Filing Date 08/25/2003		Group Art Unit 1625	
Mailed on: August 4, 2004						
CA	FR2735774	1/11/00	FR	*1* Barth et al, in French (including English bibliography and abstract, appears equivalent to US6013648)		
CA	GB2027021A	2/13/80	GB	Mechoulam et al, in English (appears equivalent to US4282248)		
CA	JP57098228	6/18/82	JP	Noda et al, in Japanese (including English bibliography and abstract)		
CA	WO 00/32200	6/8/00		Makriyannis et al, in English		
CA	WO 01/28329	4/26/01		*1* Makriyannis et al, in English		
CA	WO 01/28497	4/26/01		Makriyannis et al, in English		
CA	WO 01/28498	4/26/01		Makriyannis et al, in English		
CA	WO 01/28557	4/26/01		Makriyannis et al, in English		
CA	WO 01/29007	4/26/01		Makriyannis et al, in English		
CA	WO 01/32169	5/10/01		Fride et al, in English		
CA	WO 01/58869	8/16/01		Pandit et al, in English, first page only (including bibliography and abstract, appears equivalent to US2002/0119972)		
CA	WO 03/005960	1/23/03		*1* Makriyannis et al, in English		
CA	WO 03/020217	3/13/03		Makriyannis et al, in English		
CA	WO 03/035005	5/1/03		Makriyannis et al, in English		
CA	WO 03/063758	8/7/03		Garzon et al, in English		
CA	WO 03/064359	8/7/03		Garzon et al, in English		
CA	WO 97/00860	1/9/97		Rinaldi et al, in French (including English bibliography and abstract, appears equivalent to US6013648)		
CA	WO 99/57107	11/11/99		*1* Makriyannis et al, in English		
CA	WO 99/64389	12/16/99		Makriyannis et al, in English		

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>		Application No. 10/647,544		Inventor Alexandros Makriyannis et al	
		Title Keto Cannabinoids With Therapeutic Indications			
		Filing Date 08/25/2003		Group Art Unit 1625	
Mailed on: August 4, 2004					
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>					
Examiner Initial					
CA	Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A.; "(R)-Methanadamide: a chiral novel anandamide possessing higher potency and metabolic stability"; J. Med. Chem.; 37(12); 1889-1893; 1994; CODEN: JMCMAR; ISSN: 0022-2623; XP002040932				
CA	*1* Alo, B.I.; Kandil, A.; Patil, P. A.; Sharp, M. J.; Siddiqui, M. A.; and Snieckus, V. Sequential Directed Ortho Metalation-Boronic Acid Cross-Coupling Reactions. A general Regiospecific Route to Oxygenated Dibenzo[b,d]pyran-6-ones Related to Ellagic Acid, J. Org. Chem. 1991, 56, 3763-3768				
CA	*** Archer et al; "cannabinoids, synthesis approaches to 9-ketocannabinoids."; J. Org. Chem.; vol. 42; no. 13; 2277-2284; (1977)				
CA	*1* Arnone M., Maruani J., Chaperon P, et al, Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacol, (1997) 132, 104-106. (abstract only)				
CA	*1* Barnett-Norris et al; "Exploration of biologically relevant conformations of anandamide, . . ."; J. Med. Chem.; vol. 41; 4861-4872; 1998				
CA	*1* Beak, P.; and Brown, R A., The Tertiary Amide as an Effective Director of Ortho Lithiation, J. Org. Chem. 1982, 47, 34-36				
CA	*1* Belgaonkar et al; "synthesis of isocoumarins"; Indian J. Chem; vol. 13; no. 4; 336-338; 1975 (abstract only)				
CA	Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D; "Functional Role Of High-Affinity Anandamide Transport, as Revealed By Selective Inhibition"; Science; vol. 277; 1094-1097; 1997				
CA	Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D; "Identification and Functional Role of High Affinity Anandamide Transport"; The Neurosciences Institute (1 page)				
CA	Berdyshev EV, Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. 2000 Nov; 108(1-2):169-90				

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 10/647,544	Inventor Alexandros Makriyannis et al	
		Title Keto Cannabinoids With Therapeutic Indications		
		Filing Date 08/25/2003	Group Art Unit 1625	Docket No. UCONAP/207/US
Mailed on: August 4, 2004				
CA	Berglund et al; "Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: . . ."; Prostaglandins, leukotrienes and essential fatty acids; 59(2); 111-118; (1998). (abstract only)			
CA	Bodnar, V.N., Lozinskii, M.O., Pel'kis, P.S.; "Synthesis fo 2,5-disubstituted 1,3,4-oxadiazoles and 1,4-dihydro-1,2,4,5-tetrazines"; Ukrainskii Khimicheskii Zhurnal (Russian Edition); 48(12); 1308-1311; 1982 (abstract only)			
CA	Bracey, M et al, Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling. Science 2002; 298(5599): 1793-1796			
CA	*1* Brenneisen R, Pgli A, Elsohly MA, Henn V. Spiess Y: The effect of orally and rectally administered 9 – tetrahydrocannabinol on spasticity, a pilot study with 2 patients. Int. J. Clin Pharmacol Ther. (1996) 34:446-452. (abstract only)			
CA	*1* *** Brotchie JM: Adjuncts to dopamine replacement a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. (1998)13:871-876.			
CA	*1* Brown et al; "Synthesis and hydroboration of (-)-2-phenylapopinene, Comparison of mono(2-phenylapoisopinocampheyl)borane with its 2-methyl and 2-ethyl analogues for the chiral hydroboration of representative alkenes"; J. Org. Chem.; 55(4); 1217-1223; (1990)			
CA	*1* Buckley NE, McCoy KI, Mpzey E et al, "Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor"; Eur. J Pharmacol (2000) 396:141-149.			
CA	*1* Burstein et al; "detection of cannabinoid receptors . . ."; Biochem. Biophys. Res. Commun.; vol. 176(1); 492-497; 1991 (abstract only)			
CA	Busch-Peterson et al; "Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs"; J. Med. Chem.; 39; 3790-3796; (1996)			
CA	*1* Calignano A, La Rana G. Diuffrida A, Piomelli D; "Control of pain initiation by endogenous cannabinoids"; Nature (1998) 394:277-291. (abstract only)			
CA	Calignano A., La Rana G., Beltramo, M., Makriyannis A., Piomelli D; "Potentiation of Anandamide Hypotension by the Transport Zinhibitor, AM404"; Eur. J. Pharmacol.; 1997; 337 R1-R2			

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 10/647,544	Inventor Alexandros Makriyannis et al	
		Title Keto Cannabinoids With Therapeutic Indications		
		Filing Date 08/25/2003	Group Art Unit 1625	Docket No. UCONAP/207/US
Mailed on: August 4, 2004				
CA	Calignano A., La Rana G., Makriyannis A., Lin. S., Beltramo M., Piomelli D; "Inhibition of Intestinal Motility by Anandamide, an Endogenous Cannabinoid"; Eur. J. Pharmacol.; 1997; 340 R7-R8			
CA	Campbell FA et al; "Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review"; BMJ. 2001 Jul 7;323(7303):13-6			
CA	*1* Charalambous A. et al; "5'-azido 8-THC: A Novel Photoaffinity Label for the Cannabinoid Receptor"; J. Med. Chem., 35, 3076 - 3079 (1992)			
CA	*1* Charalambous A. et al; "Pharmacological evaluation of halogenated ..."; Pharmacol. Biochem. Behav.; vol. 40; no. 3; 509-512; 1991			
CA	*1* Cheng et al; "Relationship Between the Inhibition Constant (Ki) and the concentration of Inhibitor which causes 50% Inhibition (IC50) of an Enzymatic Reaction"; Biochem. Pharmacol., 22, 3099-3102, (1973) (abstract only)			
CA	Cherest M., Luscindi X.; "The action of acetyl chloride and of acetic anhydride on the lithium nitronate salt of 2-phenylnitroethane ..."; Tetrahedron; 42(14); 3825-3840; 1986; in French with English abstract			
CA	Cherest M., Lusinchi X.; "A novel electrophilic N-amidation via electron deficient complexes: action of ferric chloride on N-acetyloxyamides"; Tetrahedron Letters; 30(6); 715-718; 1989			
CA	*1* Colombo G, Agabio R, Diaz G. et al; "Appetite suppression and weight loss after the cannabinoid antagonist SR141716"; Life Sci. (1998) 63-PL13-PL117. (abstract only)			
CA	*** Compton D.R. et al; J. Pharmacol. Exp. Ther.; 260; 201-209; 1992			
CA	*1* Compton et al; "Synthesis and pharmacological evaluation of ether and related analogues of delta8-, delta9- and delta9,11-tetrahydrocannabinol"; J. Med. Chem; vol. 34; no. 11; 3310-3316; 1991			
CA	*1* Consroe P, Musty R, Rein J, Tillery W, Pertwee R; "The perceived effects of smoked cannabis on patents with multiple sclerosis"; Eur. Neurol. (1997) 38-44-48. (abstract only)			
CA	Coxon et al; "Derivatives of nopinone"; Aust. J. Chem.; 23; 1069-1071; (1970) (abstract only)			
CA	*1* Crawley et al; "Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents"; Pharmacology Biochemistry and Behavior; vol. 46; 967-972; 1993			



INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 10/647,544		Inventor Alexandros Makriyannis et al	
		Title Keto Cannabinoids With Therapeutic Indications			
		Filing Date 08/25/2003		Group Art Unit 1625	
Mailed on: August 4, 2004					
CA	D'Ambra et al; "C-attached aminoalkylindoles: potent cannabinoid mimetics"; Bioorg. & Med. Chem. Lett., 1996, 6(1), 17-22				
CA	*** D'Amour F.E., Smith D.L.; J. Pharmacol. Exp. Ther.; 72; 74-79; 1941				
CA	Demuynck L. et al; "Rearrangement of Indolo[2,3-a]quinolizidines to derivatives with E-azaaspidospermane skeleton"; Tetrahedron Letters; 30(6) 710-722; 1989; in French with English abstract				
CA	*1* DePetrocellis L, Melck D, Palmisano A. et al; "The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation"; Proc. Natl. Acad. Sci. USA (July 1998) 95:8375-8380.				
CA	Desarnaud F., Cadas H., Piomelli D.; "Anandamide amidohydrolase activity in rat brain microsomes"; J. Biol. Chem.; 270; 6030-6035; (1995)				
CA	Deutsch D.G. et al; "Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to cannabinoid receptor"; Biochem. Biophys. Res. Commun. 231(1); 217-221; 1997; CODEN: BBRC9; ISSN:0006-291X; XP002040933				
CA	Deutsch D.G., Chin S.A.; "Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist"; Biochemical Pharmacology; 46(5); 791-796; 1993				
CA	*1* Devane, W.A. et al; "Determination and Characterization of a Cannabinoid Receptor in a Rat Brain"; Mol. Pharmacol., 34, 605 - 613 (1988). (abstract only)				
CA	*1* Di Marzo, V., Melck, D., Bisogno, T., DePetrocellis, L.; "Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action"; Trends Neurosci. (1998) 21:521 - 528.				
CA	*** Dodd, P.R. et al, A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 226, 107 - 118 (1981).				
CA	*1* Dominiemi et al; "Synthesis of 5-(tert-Alkyl)resorcinols"; J. Org. Chem. 42(2); 344-346; (1977)				
CA	Drake et al, "classical/nonclassical hybrid cannabinoids"; J. Med. Chem.; vol. 41(19); 3596-3608 (1998)				
CA	Edery et al; "Activity of novel aminocannabinoids in baboons"; J. Med. Chem.; 27; 1370-1373 (1984)				
CA	Eissenstat et al; "Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics"; J. Med. Chem. 1995, Vol. 38, No. 16, pp. 3094-3105; XP 000651090				
CA	Fahrenholtz, K. E., Lurie, M. and Kierstead, AR. W.; "The Total Synthesis of dl-Δ9-Tetrahydrocannabinol and Four of Its Isomers"; J. Amer. Chem. Soc. 1967, 89(23), 5934-5941				

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 10/647,544	Inventor Alexandros Makriyannis et al	
		Title Keto Cannabinoids With Therapeutic Indications		
		Filing Date 08/25/2003	Group/Art Unit 1625	Docket No. UCONAP/207/US
Mailed on: August 4, 2004				
CA	*1* Fahrenholtz; "The synthesis of 2 metabolites of (-)-delta eight-tetrahydrocannabinol"; J. Org. Chem.; vol. 37(13); 1972; XP002111824			
CA	Fisera, L., Kovac, J., Lesco, J., Smahovsky, V.; "Furan derivatives. Part CLVI. 1,3-dipolar cycloadditions of heterocycles. V. Reaction of C-acetyl-N-phenylnitrilimine with furan derivatives"; Chemicke Zvesti; 35(1); 93-104 1981 (abstract only)			
CA	*1* Fride, E. & Mechoulam, R.; "Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent"; European Journal of Pharmacology, vol. 231; 313-314; 1993.			
CA	Galiegue S et al. ; "Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations"; Eur J Biochem.; 1995 Aug 15;232(1):54-61. (abstract only)			
CA	*1* Gareau, Y.; Dufresne, C.; Gallant, M.; Rochette, C.; Sawyer, N.; Slipetz, D. M.; Tremblay, N.; Weech, P. K.; Metters, K. M.; Labelle, M.; "Structure activity relationships of tetrahydrocannabinol analogs on human cannabinoid receptors"; Bioorg. Med. Chem. Lett. 1996, 6(2), 189-194			
CA	*1* Gold et al; "A comparison of the discriminative stimulus properties of delta9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys"; J. Pharmacol. Exp. Ther.; vol. 262(2); 479-486; 1992			
CA	*1* *** Green K. Marijuana smoking vs. cannabinoids for glaucoma therapy. Arch. Ophthalmol. (1998) feb 433-437.			
CA	*1* Hampson, A.J., Grimaldi M. Axpirod J. Wink D; "Cannabidiol and (-) 9 tetrahydrocannabinol are neuroprotective antioxidants"; Proc. Natl Acad Sci. USA (July 1998) 95; 8268-8273.			
CA	*1* Hargreaves, K. et al; "A new sensitive method for measuring thermal nociception in cutaneous hyperalgesia"; Pain; 32; 77-88; (1988) (abstract only)			
CA	*1* *** Hemming M, Yellowlees PM; "Effective treatment of Tourette's syndrome with marijuana"; J. Psychopharmacol, (1993) 7:389-391.			
CA	*1* Herzberg U, Eliav E, Bennett GJ, Kopin IJ; "The analgesic effects of R(+) WIN 55,212-2 mesylate, a high affinity cannabinoid agonist in a rat model of neuropathic pain"; Neurosci. Letts. (1997) 221; 157-160.			
CA	Hillard C. J., Edgemond, W. S., Jarrahan W., Campbell, W. B; "Accumulation of N-Arachidonoyl ethanolamine (Anandamide) into Cerebellar Granule Cells Occurs via Facilitated Diffusion"; Journal of Neurochemistry; 69; 631-638 (1997)			

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 10/647,544	Inventor Alexandros Makriyannis et al	
		Title Keto Cannabinoids With Therapeutic Indications		
		Filing Date 08/25/2003	Group Art Unit 1625	Docket No. UCONAP/207/US
Mailed on: August 4, 2004				
CA	Horrevoets A.J.G et al; "Inactivation of escherichia coli outer membrane phospholipase A by the affinity label hexadecanesulfonyl fluoride"; Eur. J. Biochem.; 198; 247-253; 1991			
CA	Horrevoets A.J.G et al; "Inactivation of reconstituted escherichia coli outer membrane phospholipase A by membrane-perturbing peptides results in an increased reactivity towards the affinity label hexadecanesulfonyl fluoride"; Eur. J. Biochem.; 198; 255-261; 1991			
CA	Howlett et al; "Azido and isothiocyanato substituted aryl pyrazoles bind covalently to the CB1 cannabinoid receptor and impair signal transduction"; Journal of Neurochemistry; vol. 74(5) (2000) 2174-2181; XP001097394			
CA	<b>*1* Howlett et al; "Stereochemical effects of 11-OH-delta 8 tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor"; Neuropharmacology; vol. 29(2); 161-165; 1990</b>			
CA	Huffman et al; "3-(1',1'-dimethylbutyl)--deoxy-delta 8THC and related compounds: synthesis of selective ligands for the CB2 receptor"; Bioorganic and Medicinal Chemistry; vol. 7; 2905-2914; (1999)			
CA	Huffman et al; "Stereoselective synthesis of the epimeric delta 7-tetrahydrocannabinols"; tetrahedron; vol. 51(4); 1017-1032; (1995)			
CA	<b>*1* Huffman et al; "Synthesis of 5',11 dihydroxy delta 8 tetrahydrocannabinol"; Tetrahedron, vol. 53(39), pp 13295-13306 (1997)</b>			
CA	<b>*1* Huffman et al; "Synthesis of a tetracyclic, conformationally constrained analogue of delta8-THC"; Bioorganic &amp; Medicinal Chemistry; vol. 6(12); 2281-2288; 1998; XP002123230</b>			
CA	<b>*1* Huffman et al; "Synthesis of both enantiomers of Nabilone from a common intermediate. Enantiodivergent synthesis of cannabinoids"; J. Org. Chem.; 1991, 56, 2081-2086</b>			
CA	<b>*1* *** Joy JE, Wagtson SJ, Benson JA; "Marijuana and Medicine Assessing the Science Base"; National Academy Press, Washington, DC, USA (1999).</b>			
CA	Kaminski NE; "Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors"; J Neuroimmunol. 1998 Mar 15;83(1-2):124-32			
CA	Kawase M. et al; "Electrophilic aromatic substitution with N-methoxy-N-acylnitrenium ions generated from N-chloro-N-methoxyamides: synthesis of nitrogen heterocyclic compounds bearing a N-methoxyamide group"; J. Org. Chem.; 54; 3394-3403; 1989			

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 10/647,544	Inventor Alexandros Makriyannis et al	
	Title Keto Cannabinoids With Therapeutic Indications		
	Filing Date 08/25/2003	Group Art Unit 1625	Docket No. UCONAP/207/US
Mailed on: August 4, 2004			
CA	Khanolkar A., Abadji V., Lin S., Hill W., Taha G., Abouzid K., Meng Z., Fan P., Makriyannis A.; "Head group analogues of arachidonylethanolamide, the endogenous cannabinoid ligand"; J. Med. Chem.; vol. 39(22); 4515-4519; (1996)		
CA	Khanolkar et al; "Molecular probes for the cannabinoid receptors"; Chemistry and Physics of Lipids; 108; 37-52; (2000)		
CA	Klein T.W. et al, "The cannabinoid system and cytokine network"; Proc Soc Exp Biol Med. 2000 Oct; 225(1):1-8; <b>(abstract only)</b>		
CA	Klein TW et al, "Cannabinoid receptors and immunity"; Immunol Today; 1998 Aug; 19(8):373-81		
CA	Koutek B. et al; "Inhibitors of arachidonyl ethanolamide hydrolysis"; J. Biol. Chem.; 269(37); 22937-40; 1994; CODEN: JBCHA3; ISSN: 0021-9258; XP002040931		
CA	Kumar RN, et al; "Pharmacological actions and therapeutic uses of cannabis and cannabinoids"; Anesthesia, 2001, 56: 1059-1068 <b>(abstract only)</b>		
CA	Lan, R et al; "Structure activity relationships of pyrazole derivatives as cannabinoid receptor antagonists"; J. Med. Chem.; vol. 42(4); 769-776; (1999)		
CA	<b>*1* Lavallo et al; "Efficient conversion of (1R, 5R)-(+)-alpha-pinene to (1S, 5R)-(-)-nopinene"; J. Org. Chem.; vol. 51(8); 1362-1365; (1986)</b>		
CA	Lin S., Khanolkar A., Fan P., Goutopolous A., Qin C., Papahadjis D., Makriyannis A.; "Novel Analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 Cannabinoid Receptors and Metabolic Stability"; J. Med. Chem.; vol. 41; 5353; 1998		
CA	<b>*1* Loev, B., Bender, P. E., Dowalo, F., Macko, E., and Fowler, P.; "Cannabinoids. Structure-Activity Studies Related to 1,2-Dimethylheptyl Derivatives"; J. Med. Chem.; vol. 16(11); 1200-1206; 1973</b>		
CA	Lozinskii, M.O., Bodnar, V.N., Konovalikhin, S.V., D'yachenko, O.A., Atovmyan, L.O.; "Unusual transformations of arylhydrazonoyl chlorides of oxalic acid ethyl ester"; Izvestiya Akademii Nauk SSSr, Seriya Khimicheskaya; 11; 2635-2637; 1990 <b>(abstract only)</b>		
CA	<b>*1* Ludt, R.E. et al; "A comparison of the synthetic utility of n-butyllithium and lithium diisopropylamide in the metalations of N,N-dialkyltouamides"; J. Org. Chem.; 38(9); 1668-1674 (1973)</b>		
CA	<b>*** Maccarron M., Endocannabinoids and their actions. Vitamins and Hormones 2002;65:225-255</b>		

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 10/647,544	Inventor Alexandros Makriyannis et al	
	Title Keto Cannabinoids With Therapeutic Indications		
	Filing Date 08/25/2003	Group Art Unit 1625	Docket No. UCONAP/207/US
Mailed on: August 4, 2004			
CA	Mackie K., Devane W.A., Hille B.; "Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells"; Mol. Pharmacol; 44; 498-0503 (1993)		
CA	*1* *** Markwell et al; Anal. Biochem.; 87:206 (1978)		
CA	*1* Martin et al; "Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs"; Pharmacol. Biochem. Behav.; vol. 40(3); 471-478; 1991		
CA	*1* Martyn CN. Illis LS, Thom J.; "Nabilone in the treatment of multiple sclerosis"; Lancet (1995) vol. 345; pp. 579.		
CA	*1* Matsumoto et al; "Cannabinoids 1.1-amino-and 1 mercapto-7,8,9,10-tetrahydro-6h-dibenzo[b,d]pyrans"; J. of Med. Chem.; vol. 20(1); 17-24; 1977; XP00211825		
CA	*1* *** Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur. Arch. Psychiat. Clin. Neurosci. (1990), Z40:1-4.		
CA	*1* Mavromoustakos, T. et al; "Studies on the thermotropic effects of cannabinoids on phosphatidylcholine bilayers using differential scanning calorimetry and small angle X-ray diffraction"; Biochimica et Biophysica Acta; vol 1281(2); 1996; XP002111823		
CA	Mechoulam et al; "Stereochemical Requirements for cannabinoid activity"; J. Med. Chem.; 23(10); 1068-1072; (1980)		
CA	Mechoulam et al; "Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative"; Tetrahedron Asymmetry; 1: 311-314; (1990) (abstract only)		
CA	*** Mechoulam et al; Tetrahedron Asymmetry; 1: 315-318; (1990)		
CA	*1* *** Mechoulam, "Cannabinoids as therapeutic agents"; CRC press, 1986		
CA	*1* Meltzer et al; "An improved synthesis of cannabinol and cannabiorcol"; Synthesis; 1981:985 (1981)		
CA	*** Melvin et al; drug design and discovery; 13; 155-166 (1995)		
CA	Melvin et al; "Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs"; Mol. Pharmacol.; 44(5); 1008-1015 (1993)		
CA	*1* Merck Index; 11th edition; "Tetrahydrocannabinols" compound no. 9142; 1989		

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 10/647,544	Inventor Alexandros Makriyannis et al	
	Title Keto Cannabinoids With Therapeutic Indications		
	Filing Date 08/25/2003	Group Art Unit 1625	Docket No. UCONAP/207/US
Mailed on: August 4, 2004			
CA	*1* *** <i>Morgan Dr: Therapeutic Uses of Cannabis. Harwood Academic Publishers, Amsterdam. (1997).</i>		
CA	*1* *** <i>Morris, S.; Mechoulam, R.; and Irene, Y., Halogenation of phenols and Phenyl ethers with Potassium Halides in the Presence of 18-Crown-6 on Oxidation with m-Chloroperbenzoic Acid, J. Chem. Soc., Perkin Trans. 1 1987, 1423-1427</i>		
CA	*1* *** <i>Muller-Vahl KB, Kolbe H, Schneider U, Emrich, HM Cannabis in movement disorders. Porsch. Kompicmentarmed (1999) 6 (suppl. 3) 23-27.</i>		
CA	*1* *** <i>Muller-Vahl KB, Schneider U, Kolbe H, Emrich, HM. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am. J. Psychiat. (1999) 156-195.</i>		
CA	*** <i>Nahas G, Marijuana and Medicine; 1999, Human Press Inc., Totowa, NJ</i>		
CA	Neunhoeffter O., Gottschlich R.; "Acylation activity of O-acylated hydroxylamine derivatives"; Justus Liebigs Ann. Chem.; 736; 100-109; 1970; in German with English abstract		
CA	*1* Novak, J et al; "Cannabis, part 27, synthesis of 8-, 10- and 11-oxygenated cannabinoids; J. Chem. Soc. Perkin Trans.; 2867-2871; (1983) (abstract only)		
CA	*1* Nye et al; "High affinity cannabinoid binding sites in brain membranes labelled with [H]-5'-trimethylammonium delta8-tetrahydrocannabinol"; J. Pharmacol. Exp. Ther.; vol. 234(3); 784-791; 1985		
CA	*** <i>Palmer et al; current pharmaceutical design; 6; 1381-1397; (2000)</i>		
CA	*1* Papahatjis et al; "A new ring-forming methodology for the synthesis of conformationally constrained bioactive molecules"; Chemistry Letters, 192; (2001)		
CA	*1* Papahatjis et al; "Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta8-tetrahydrocannabinols"; J. Med. Chem.; 41(7); 1195-1200; (1998)		
CA	Pertwee et al; "AM630, a competitive cannabinoid receptor agonist"; Life Sci. 1995, 56(23/24), 1949-1955; XP 000653566		
CA	Pertwee et al; "Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens"; Eur. J. Pharmacol. 1995, 284, 241-247; XP-001041044		
CA	*** <i>Pertwee et al; Br. J. Pharmacol.; 105; 980 1992</i>		

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 10/647,544	Inventor Alexandros Makriyannis et al	
		Title Keto Cannabinoids With Therapeutic Indications		
		Filing Date 08/25/2003	Group Art Unit 1625	Docket No. UCONAP/207/US
Mailed on: August 4, 2004				
CA	*1* Pertwee; Pharmacology of cannabinoid CB1 and CB2 receptors"; Pharmacol. Ther., vol. 74(2); pp129-180; (1997); XP002226467			
CA	Petrov, M.L., Terent'eva, N.A., Potekhin, K.A., Struchkov, Yu. T.; ".alpha.,.beta.-unsaturated thiolates and their analogs in cycloaddition reactions. XVIII. Reaction of (2-phenylethynyl)tellurolates with C-ethoxycarbonyl-N-Phenylnitrilimine"; Zhurnal Organicheskoi Khimii; 29(7); 1372-1378; (1993) (abstract only)			
CA	*1* *** Pinnegan-Ling D, Musty R.; Marinol and phantom limb pain: a case study. Proc Inv. Cannabinoid Rea. Sec. (1994):53.			
CA	Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xiw X-Q., Makriyannis A.; "Structural determinants for recognition and translocation by the anandamide transporter"; Proc. Natl. Acad. Sci. USA; 96; 5802-5807; (1999)			
CA	*1* Pitt et al; "The synthesis of Deuterium, carbon-14 and carrier free tritium labelled cannabinoids"; Journal of Labelled Compounds; vol. 11(4); 551-575; 1975; XP002123229			
CA	*** Porreca F., Mosberg H.I., Hurst R., Hruby V.J., Burks T.F.; "Roles of mu, delta and kappa opiod receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse"; J. Pharmacol. Exp. Ther.; 230; 341-348; (1994)			
CA	*1* Razdan et al; "Drugs delivered from cannabinoids. 6. .Synthesis of cyclic analogues of dimethylheptylpyran"; J. Med. Chem.; vol. 19(5); 719-721; 1976 (abstract only)			
CA	*1* Reggio et al; "Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach"; J. Med. Chem. United States; vol. 36(12); 1761-1771; 1993			
CA	*1* Rhee, M. H.; Vogel, Z.; Barg, J.; Bayewitch, M.; Levy, R.; Hanus, L.; Breuer, A.; and Mechoulam, R.; "Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylcyclase"; J. Med. Chem. 1997, 40(20); 3228-3233			
CA	*** Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs. 2001 Mar;2(3):399-414			
CA	*1* Richardson JD, Aanonsen I, Hargreaves KM; "Antihyperalgesic effects of a spinal cannabinoids"; Eur. J. Pharmacol. (1998) 346:145-153.			
CA	*1* Richardson JD, Kilo S. Hargreaves KM; "Cannabinoids reduce dryperalgesia and inflammation via interaction with peripheral CB1 receptors"; Pain (1998) 75:111-119.			


INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 10/647,544	Inventor Alexandros Makriyannis et al	
		Title Keto Cannabinoids With Therapeutic Indications		
		Filing Date 08/25/2003	Group Art Unit 1625	Docket No. UCONAP/207/US
Mailed on: August 4, 2004				
CA	Rinaldi-Carmona et al; "Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist"; Life Sci.; vol. 56(23/24); 1941-1947 (1995)			
CA	Rinaldi-Carmona et al; "SR141716A, a potent and selective antagonist of the brain cannabinoid receptor"; FEBS Lett.; 350; 240-244; (1994)			
CA	<b>*1* Rompp Chemie Lexikon; Falbe and Regitz; "band 1-A-C1, 8"; Aufl, Thieme Verlag; Stuttgart, S 569-570; 1989</b>			
CA	Santus, Maria; "Studies on thioamides and their derivatives. IX. Synthesis of the derivatives of 1,2,4,5-tetrazine"; Acta Polonae Pharmaceutica; 50(2-3); 183-188; 1993 (abstract only)			
CA	Schatz AR et al; "Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system"; Toxicol Appl Pharmacol. 1997 Feb; 142(2):278-87			
CA	<b>*1* *** Schuel, H., Burkman, L.J., Picone, R.P., Bo, T., Makriyannis, A., Cannabinoid receptors in human sperm. Mol. Biol. Cell., (1997) (8), 325a.</b>			
CA	<b>*** Serdarevich B., Carroll K.K., "Synthesis and characterization of 1- and 2-monoglycerides of anteiso fatty acids"; J. Lipid Res.; 7; 277-284; (1966)</b>			
CA	Shawali, A.S., Albar, H.A.; "Kinetics and mechanism of dehydrochlorination of N-aryl-C-ethoxycarbonyl formohydrazidoyl chlorides"; Canadian Journal Of Chemistry; 64(5); 871-875; 1986 (abstract only)			
CA	<b>*1* *** Shen M. Thayer SA: Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol (1996) 54:459-462.</b>			
CA	Shim et al; "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis"; J. Med. Chem.; 1998, 41(23); 4521-4532; XP-002212407			
CA	Shim et al; "Unified pharmacophoric model for cannabinoids and aminoalkylindoles derived from molecular superimposition of CB1 cannabinoid receptor agonists CP55244 and WIN55212-2"; ACS Symposium series, 1999 719 (rational drug design), 165-184; XP-001095771			
CA	Showalter et al; "Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands"; J. Pharmacol. Exp. Ther., 1996 278(3) 989-999; XP-001097918			



INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 10/647,544	Inventor Alexandros Makriyannis et al	
		Title Keto Cannabinoids With Therapeutic Indications		
		Filing Date 08/25/2003	Group Art Unit 1625	Docket No. UCONAP/207/US
Mailed on: August 4, 2004				
CA	*1* *** Simiand J, Keane M, Keane PE, Soubrie P: SR 141716, A CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. <i>Behav. Pharmacol</i> (1998) 9:179-181.			
CA	*1* Smith P.B. et al; "The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice"; <i>Journal of Pharmacology and Experimental Therapeutics</i> ; vol. 270(1):219-227; 1994			
CA	*1* *** Terranova J-P, Storme J-J Lafon N et al; "Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716"; <i>Psycho-pharmacol</i> (1996) 126:165-172.			
CA	Tius et al; "Conformationally restricted hybrids of CP-55,940 and HHC: Stereoselective synthesis and activity"; <i>Tetrahedron</i> ; 50 (9); 2671-2680; (1994) (abstract only)			
CA	Twitchell, W. et al; "Cannabinoids inhibit N- and P/Q type calcium channels in cultured rat hippocampal neurons"; <i>Journal of Neurophysiology</i> ; 78(1); 43-50; 1997 (abstract only)			
CA	*** Ueda, N., <i>Endocannabinoid hydrolases. Prostaglandins &amp; Other Lipid Mediators</i> 2002;68-69:521-534			
CA	*** Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R.; "Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase"; <i>J. Neurochem.</i> ; 61(1) 352-355; (1993)			
CA	*1* *** Wagner JA, Varga K, Jarai Z, Kunos G; 'Mesenteric vasodialtion mediated by endothelia anandamide receptors'; <i>Hypertension</i> (1999) 33:429-434.			
CA	*1* Watanabe, T.; Miyaura, N.; and Suzuki, A.; "Synthesis of Sterically Hindered Biaryls via the Palladium Catalyzed Cross-Coupling Reaction of Arylboronic Acids or their Esters with Haloarenes"; <i>Synlett</i> 1992, 207-210			
CA	Wiley et al; "Structure activity relationships of indole and pyrrole derived cannabinoids"; <i>J. Pharmacol. Exp. Ther.</i> 1998, 285(3), 995-1004; XP-001097982			
CA	Wilson et al; "9-nor-delta8-tetrahydrocannabinol, a cannabinoid of metabolic intersts"; <i>J. Med. Chem.</i> ; 17(4); 475-476; (1974)			
CA	Wilson et al; "Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs"; <i>J. Med. Chem.</i> ; 18(7); 700-703; (1975)			
CA	Wilson et al; "9-nor-9-hydrohexahydrocannabinols. Synthesis, some behavioral and analgesic properties, and comparison with the tetrahydrocannabinols"; <i>J. Med. Chem.</i> ; 19(9); 1165-1167; (1976)			

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>		Application No. 10/647,544	Inventor Alexandros Makriyannis et al	
		Title Keto Cannabinoids With Therapeutic Indications		
		Filing Date 08/25/2003	Group Art Unit 1625	Docket No. UCONAP/207/US
<b>Mailed on: August 4, 2004</b>				
CA	Yamada et al; "(Aminoalkyl)indole isothiocyanates as potential electrophilic affinity ligands for the brain cannabinoid receptor"; J. Med. Chem. 1996, vol. 39(10), 1967-1974			
CA	Yan, Guo et al; "Synthesis and pharmacological properties of 11-hydroxy-3-(1'-1'-dimethylheptyl)hexahydrocannabinol: a high affinity cannabinoid agonist"; J. Med. Chem.; vol. 37(16); 2619-2622; (1994)			
CA	<b>*1* Yan Guo et al; "(-)-11-hydroxy-7'-isothiocyanato-1'-1'dimethylheptyl-delta8-THC: a novel probe for the cannabinoid receptor in the brain"; J. Med. Chem.; 37(23); 3867-3870; (1994)</b>			
Examiner <b>AW/AYR</b>		Date Considered		
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.				

G:\AYR saved docs\Filing Docs\Uconap\uconap207us regular of uconap.200.us\8-04 IDS.doc



<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>	Application No. 18/647,544	Inventor Alexandros MAKRIYANNIS et al	
	Title KETO CANNABINOIDS WITH THERAPEUTIC INDICATIONS		
	Filing Date Aug. 25, 2003	Group Art Unit 1614	Docket No. UCONAP/207/US

**UNITED STATES PATENT DOCUMENTS**

Examiner Initial	Document No.	Date	Name	Class
CA	3,656,906		F. J. Bullock	
CA	3,838,131		Gauthier et al.	
CA	4,382,943		Winter et al.	
CA	5,576,436		McCabe et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document No.	Date	Country	Name	Translation

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial	
CA	Database CAPLUS on STN, AN 1991: 679813, NAKAYAMA et al. "Preparation of 6H-dibenzo[b,d]pyran-6-ones and their use as aldoses reductase inhibitors", Abstract, JP 02304080 A2, 17 December 1990 (17.12.1990), see entire abstract.
CA	International Search Report for International Application No. PCT/US03/26609 mailed on April 29, 2004

Examiner <b>AW/ARKH</b>	Date Considered
----------------------------	-----------------

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

\\PATLAW5\C-PATLAW5\AYR saved docs\Filing Docs\Uconap\uconap207us regular of uconap.200.us\uconap207us 5-20-04